This stock is making its shareholders smile on Tuesday. Let's find out why. The post Why is this ASX 200 share charging 7% higher today? appeared first on The Motley Fool Australia.

FDA approved Pylarify TruVu, a higher-radioactivity-concentration formulation of piflufolastat F 18 designed to increase batch size and distribution efficiency while maintaining the established ...

Manufacturing optimization is projected to expand batch output by ~50%, improving supply reliability and supporting higher-throughput PSMA PET imaging services. Increased radioactivity extends shelf ...

A new study isolated DNA from the tumours of 500 cats across 13 different tumour types and mapped the sequence of 1,000 genes often found mutated in human cancers.

I was diagnosed with triple-negative breast cancer with lymph-node metastasis at 29 weeks pregnant. I was 37 years old. My cancer diagnosis revealed to me the complexities of being a patient in two ...

The Life Vincent Pallotti Hospital in Cape Town has recently improved its cancer diagnostics by installing a digital PET-CT (positron emission tomography-computed tomography) scanner. This scanner, a ...

The FDA has approved a new formulation of an F 18 prostate-specific membrane antigen imaging agent for men with prostate cancer, according to an industry press release. As Healio previously reported, ...

New formulation of its widely-used U.S. market-leading PSMA PET imaging agentcombines thediagnostic performance of PYLARIFY® (piflufolastat F 18) ...

The U.S. Food and Drug Administration on Friday approved a new formulation of Lantheus Holdings' prostate cancer imaging ...

The University of Oklahoma College of Pharmacy is constructing a $16 million cyclotron facility to produce radiopharmaceuticals, enhancing cancer treatment and imaging capabilities in Oklahoma.

Radiation therapy works by using high-energy X-rays to kill cancer cells. MSK offers precise radiation therapy that kills throat cancer cells with fewer side effects from radiatio ...

Researchers at Moffitt Cancer Center have identified distinct spatial tumor–immune ecosystems that predict whether patients with advanced non–small-cell lung cancer will benefit from immunotherapy.